Excelsior Biopharma Inc.

TPEX:6496 Stock Report

Market Cap: NT$1.4b

Excelsior Biopharma Past Earnings Performance

Past criteria checks 0/6

Excelsior Biopharma's earnings have been declining at an average annual rate of -71%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been declining at an average rate of 18.4% per year.

Key information

-71.0%

Earnings growth rate

-71.0%

EPS growth rate

Healthcare Industry Growth9.1%
Revenue growth rate-18.4%
Return on equity-6.9%
Net Margin-8.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital

Apr 01
Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital

Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?

Mar 11
Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?

Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?

Feb 09
Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?

Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?

Jan 11
Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?

Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)

Dec 22
Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)

Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative

Nov 30
Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative

Revenue & Expenses Breakdown

How Excelsior Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6496 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24830-7136275
30 Jun 24799-8635475
31 Mar 24774-10134171
31 Dec 23772-9132663
30 Sep 23730-9830955
30 Jun 23719-7129942
31 Mar 23686-4827743
31 Dec 22672-3427442
30 Sep 22872-3528154
30 Jun 22997-3826760
31 Mar 221,167-2826352
31 Dec 211,338-1624656
30 Sep 211,315-923053
30 Jun 211,3821221853
31 Mar 211,4432520961
31 Dec 201,4443521157
30 Sep 201,5245521362
30 Jun 201,5186220859
31 Mar 201,5176821452
31 Dec 191,5407121651
30 Sep 191,53810622242
30 Jun 191,59414823941
31 Mar 191,64117425743
31 Dec 181,68922226439
30 Sep 181,68923027258
30 Jun 181,71124928058
31 Mar 181,69628127355
31 Dec 171,71628028260
30 Sep 171,71926927861
30 Jun 171,70226227663
31 Mar 171,62822028064
31 Dec 161,53518027066
30 Sep 161,42516226646
30 Jun 161,31212825442
31 Mar 161,28113123639
31 Dec 151,23814322834
30 Sep 151,21614320838
30 Jun 151,21015320850
31 Mar 151,18015821660
31 Dec 141,14715420271
31 Dec 1395415726912

Quality Earnings: 6496 is currently unprofitable.

Growing Profit Margin: 6496 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6496 is unprofitable, and losses have increased over the past 5 years at a rate of 71% per year.

Accelerating Growth: Unable to compare 6496's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6496 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6.3%).


Return on Equity

High ROE: 6496 has a negative Return on Equity (-6.92%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies